| Ticker | REPL |
|---|---|
| ISIN | US76029N1063 |
| Sector | Atención sanitaria |
| Mercado | NASDAQ |
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneo...
El precio actual de Replimune Group, Inc. (REPL) es de 2,77 , con una variación del 14,46%.
Replimune Group, Inc. opera en el sector Healthcare, industria Biotechnology.
Compara brokers con acceso a las principales bolsas internacionales, con bajas comisiones, custodia y herramientas de análisis para invertir en acciones.
Compara brokers para acciones